Phase 0 Clinical Chemoprevention Trial of the AKT Inhibitor SR13668

PURPOSE: SR13668, an orally active AKT pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reid, Joel M., Walden, Chad, Qin, Rui, Allen Ziegler, Katie L., Haslam, John L., Rajewski, Roger A., Warndahl, Roger, Fitting, Cindy L., Boring, Daniel, Szabo, Eva, Crowell, James, Perloff, Marjorie, Jong, Ling, Mandrekar, Sumithra J., Ames, Matthew M., Limburg, Paul J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061470/
https://ncbi.nlm.nih.gov/pubmed/21372034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0313
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados